Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review
JMIR Medical Informatics · 12.11.2026 · 14 · e86011-e86011
DOI: 10.2196/86011 ↗Kurz gefasst
Scoping Review in der Zeitschrift JMIR Medical Informatics, online erschienen am 12.11.2026. Verfasst von Lampros Mpaltadoros und 10 weiteren Autor:innen. Beteiligte Einrichtung: Information Technologies Institute, Centre for Research and Technology Hellas, 6th Km Charilaou-Thermi, Thessaloniki, 57001, Greece, +306973900849. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Telemedicine, Digital Technology. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Decentralized clinical trials (DCTs) are reshaping clinical research through digital technologies such as telemedicine, mobile apps, wearable and sensor-based tools, and digital platforms. These technologies can support participation, safety, accessibility, data collection, monitoring, and trial operations. Although DCT adoption accelerated during the COVID-19 pandemic, the commercial technology landscape remains fragmented and continues to evolve rapidly. There is limited understanding of how commercial technologies align with operational activities across the DCT life cycle. The Basic Building Block (BBB) framework used in this review divides the DCT life cycle into 7 functional areas: setup and design; recruitment and enrollment; data acquisition and processing; operation and coordination; patient engagement; intervention and follow-up; and close-out and reporting.
Objective
This scoping review aimed to map commercial technologies supporting DCT operations and assess their availability and functional alignment with clinical trial processes.
Methods
A scoping review of commercial technologies was conducted from January 2024 to June 2025 to update a previous 2020 technology scan, with a search rerun in June 2026 for update and verification purposes. Eligible technologies were commercially available, publicly documented, and relevant to at least 1 BBB. The review was reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews), with search reporting guided by PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Literature Search extension) where applicable. Seven 2-person reviewer groups reassessed previously identified technologies and identified additional technologies by analyzing publicly available English-language sources, including vendor and company websites, product documentation, public reports, case studies, company announcements, and relevant academic literature. Technologies were categorized by BBB coverage, classified as single-BBB if they supported 1 BBB and multiple-BBB if they supported more than 1 BBB, and analyzed using a co-occurrence matrix.
Results
The final catalog included 329 commercial technologies, spanning the DCT life cycle. Most were multiple-BBB technologies, with 293 multiple-BBB and 36 single-BBB technologies. Operation and coordination was the most frequently covered BBB (n=220), followed by data acquisition and processing (n=212), setup and design (n=189), patient engagement (n=165), close-out and reporting (n=125), intervention and follow-up (n=122), and recruitment and enrollment (n=120). The strongest co-occurrence pairings were data acquisition and processing with operation and coordination; setup and design with operation and coordination; and setup and design with data acquisition and processing. The weakest pairings involved close-out and reporting with intervention and follow-up, with recruitment and enrollment, and with patient engagement.
Conclusions
This scoping review provides an updated structured mapping of 329 commercial technologies supporting DCT operations. By combining a commercial technology scan with the BBB framework, the review quantifies functional coverage and co-occurrence across the DCT life cycle. The findings can support technology selection for decentralized and hybrid trials while highlighting operational areas where technology coverage seems to be less commonly combined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Information Technologies Institute, Centre for Research and Technology Hellas, 6th Km Charilaou-Thermi, Thessaloniki, 57001, Greece, +306973900849.
- Institute of eHealth, FH JOANNEUM GmbH - University of Applied Sciences, Graz, Austria.
- Vaccines Research Department, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain.
- BBMRI-ERIC, Graz, Austria.
Zitieren
APA
Mpaltadoros, L., Huber, S., Stavropoulos, T. G., Buchgraber-Schnalzer, B., Fons-Martínez, J., Murciano-Gamborino, C., Alcalde, B., Pérez-Breva, L., Nikolopoulos, S., Kompatsiaris, I., & Hanke, S. (2026). Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review. JMIR Medical Informatics, 14, e86011-e86011. https://doi.org/10.2196/86011
Vancouver
Mpaltadoros L, Huber S, Stavropoulos TG, Buchgraber-Schnalzer B, Fons-Martínez J, Murciano-Gamborino C, et al. Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review. JMIR Medical Informatics. 2026;14:e86011-e86011. doi:10.2196/86011
BibTeX
@article{Mpaltadoros2026,
author = {Mpaltadoros, Lampros and Huber, Simone and Stavropoulos, Thanos G and Buchgraber-Schnalzer, Bianca and Fons-Martínez, Jaime and Murciano-Gamborino, Carlos and Alcalde, Baptiste and Pérez-Breva, Lina and Nikolopoulos, Spiros and Kompatsiaris, Ioannis and Hanke, Sten},
title = {Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review},
journal = {JMIR Medical Informatics},
year = {2026},
volume = {14},
pages = {e86011--e86011},
doi = {10.2196/86011}
}
EUVIMED